ASTAL LABORATORIES LIMITED

BSE: ASTALLTD512600ISIN INE307N01014

Healthcare
Pharmaceuticals

Share price

₹58.47+7.22 (+14.09%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹99.90
52W low: ₹49.99
Off 52W high: -41.47%
1M return: -17.96%
3M return: -28.04%
6M return: -7.34%
1Y return: -39.66%
20D avg volume: 22,717
50 DMA: ₹70.87
200 DMA: ₹75.62

Key ratios Consolidated

Market cap: ₹256.09 Cr
Current price: ₹58.47
52W high / low: ₹99.90 / ₹49.99
Face value: ₹10.00
P/E: 0.00
P/B: —
EPS (TTM): ₹0.00
Book value / share: —
ROE: —
ROCE: 5.60%
Operating margin: —
Net margin: —
Debt / equity: 0.15
Net debt: ₹47.78 Cr
Interest cover: 9.73
Dividend yield: —
Dividend / share (TTM): —
Payout: —
Cash conversion cycle: 146.6 days

Financials

Metric	Q1 FY27	Q4 FY26	Q4 FY25
Income statement
	100.94	134.05	—
	0.14	0.10	—
	101.07	134.15	—
	90.72	125.81	—
	100.12	108.25	—
	0.00	0.00	—
	3.15	3.72	—
	1.18	1.09	—
	0.86	0.86	—
	2.82	2.53	—
	10.35	8.34	—
	0.00	0.00	—
	10.35	8.34	—
	0.93	0.66	—
	9.42	7.68	—
	2.19	2.04	—
Key metrics
	12.39	10.29	—
	12.30%	7.70%	—
	9.30%	5.70%	—
	—	2.70%	—

Metric	FY26	FY25
Income statement
	249.13	—
	0.22	—
	249.35	—
	231.62	—
	224.91	—
	0.00	—
	5.02	—
	2.03	—
	1.23	—
	4.32	—
	17.73	—
	0.00	—
	17.73	—
	3.02	—
	14.71	—
	8.62	—
Key metrics
	20.99	—
	8.40%	—
	5.90%	—
	5.60%	—
	-19.09	—
	-1.20	—
	0.15	—
	47.78	—
	146.6	—
Balance sheet
	518.19	—
	243.50	—
	1.30	—
	156.35	—
	67.52	—
	18.04	—
	63.71	—
	123.80	—
	164.29	—
	49.08	—
	30.44	—
	18.64	—
	333.76	—
Cash flow
	-17.70	—
	-2.17	—
	2.58	—
	1.39	—

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	39.51	40.92	52.24	37.52	25.33	23.47	14.46	13.16	13.15	12.25	8.41	1.62
	0.03	0.07	0.04	0.03	0.06	0.04	0.06	—	0.03	—	—	—
	39.55	40.98	52.27	37.55	25.38	23.50	14.52	13.16	13.18	12.25	8.41	1.62
	34.59	39.51	49.14	34.08	22.59	19.65	11.50	10.39	10.84	11.69	7.92	1.60
	40.82	36.23	54.49	39.08	23.08	24.84	12.28	13.10	11.59	—	—	—
	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	11.81	7.70	1.55
	0.62	0.81	0.44	0.42	0.45	0.09	0.41	0.43	0.41	0.39	0.05	0.01
	0.33	0.47	0.33	0.31	0.30	0.27	0.28	0.09	0.06	—	—	—
	0.18	0.32	0.12	0.12	0.12	0.10	0.08	0.03	0.01	0.02	0.01	—
	0.65	0.46	1.12	0.41	0.26	0.84	0.40	0.34	0.43	0.53	0.17	0.03
	4.96	1.47	3.13	3.47	2.79	3.85	3.02	2.77	2.34	0.56	0.49	0.03
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	—	—
	4.96	1.47	3.13	3.47	2.79	3.85	3.02	2.77	2.34	0.56	0.49	0.03
	1.25	0.39	0.77	0.89	0.70	1.10	0.53	0.77	0.65	—	—	—
	3.71	1.09	2.36	2.58	2.09	2.75	2.49	2.00	1.69	0.56	0.49	0.03
	0.86	0.29	2.19	2.40	2.12	2.80	2.53	2.04	1.72	1.10	1.01	0.07
Key metrics
	5.47	2.26	3.58	3.90	3.21	4.22	3.38	2.89	2.41	0.58	0.50	0.03
	13.80%	5.50%	6.90%	10.40%	12.70%	18.00%	23.40%	22.00%	18.30%	4.70%	5.90%	1.90%
	9.40%	2.70%	4.50%	6.90%	8.30%	11.70%	17.20%	15.20%	12.90%	4.60%	5.80%	1.90%
	—	0.60%	—	8.50%	—	11.30%	—	—	—	—	—	—
	56.00%	74.40%	261.30%	185.10%	92.60%	91.60%	71.90%	712.30%	—	—	—	—
	77.50%	-60.40%	-5.20%	29.00%	23.70%	391.10%	408.20%	6,566.70%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22
Income statement
	170.19	156.00	64.23	23.65	3.43	—
	0.17	0.19	0.13	0.01	0.18	0.21
	170.35	156.19	64.36	23.66	3.61	0.21
	157.32	145.32	52.38	22.57	3.58	0.23
	170.62	152.88	61.81	—	—	—
	0.00	0.00	0.00	22.40	3.35	—
	2.29	2.11	1.34	0.47	0.06	0.09
	1.44	1.41	0.70	—	—	—
	0.74	0.69	0.22	0.03	0.01	0.01
	2.64	2.24	2.00	0.74	0.15	0.13
	13.03	10.87	11.98	1.09	0.03	-0.02
	0.00	0.00	0.00	—	—	—
	13.03	10.87	11.98	1.09	0.03	-0.02
	3.30	2.75	3.05	0.30	0.02	—
	9.74	8.12	8.93	0.79	0.02	-0.02
	5.74	4.76	9.08	1.55	0.04	—
Key metrics
	15.21	12.97	12.90	1.12	0.04	-0.01
	8.94%	8.30%	20.10%	4.70%	1.20%	-4.80%
	5.72%	5.20%	13.90%	3.30%	0.60%	-9.50%
	—	3.70%	34.70%	—	—	—
	122.70%	142.90%	171.60%	589.50%	1,533.30%	—
	4.39%	-9.10%	1,030.40%	3,850.00%	200.00%	—
	—	-3.49	-12.52	—	—	—
	—	-0.38	-1.40	—	—	—
	—	0.04	0.37	—	—	—
	—	11.26	11.54	—	—	—
	—	110.0	179.9	—	—	—
Balance sheet
	—	399.57	63.34	—	—	—
	—	103.26	45.64	—	—	—
	—	0.70	1.73	—	—	—
	—	72.30	27.66	—	—	—
	—	28.78	14.76	—	—	—
	—	1.49	1.49	—	—	—
	—	11.36	11.44	—	—	—
	—	54.07	10.77	—	—	—
	—	71.11	26.77	—	—	—
	—	11.96	13.27	—	—	—
	—	11.59	12.81	—	—	—
	—	0.37	0.46	—	—	—
	—	327.16	35.99	—	—	—
Cash flow
	—	-3.08	-12.52	—	—	—
	—	-1.28	-7.81	—	—	—
	—	4.55	3.29	—	—	—
	—	0.41	0.00	—	—	—

Compounded growth

Standalone

Sales CAGR 3Y: +256.95%
Sales CAGR 5Y: —
Profit CAGR 3Y: +640.47%
Profit CAGR 5Y: —
Sales YoY (TTM): +122.70%
Profit YoY (TTM): +4.39%

Consolidated

Sales CAGR 3Y: —
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): —
Profit YoY (TTM): —

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 4.59%

Quarter	September 2026	June 2026
Promoter %	4.59%	4.53%

Holder	Type	Holding	Previous	Change
SESHA SAI NIKHIL CHINTALAPATI	Public	11.38%	11.38%	0.00%
SURYANARAYANA RAJU RUDRARAJU	Public	6.75%	6.75%	0.00%
KOMMERA HARISH	Public	6.43%	6.43%	0.00%
ACESO RESEARCH LABS LLP	Promoter	4.59%	4.53%	+0.06%
AMIT MISHRA	Public	4.57%	4.57%	0.00%
ABRAHAM GEORGE	Public	4.41%	4.40%	+0.01%
LIJU MATHEW	Public	3.81%	3.81%	0.00%
PAVANI VUPPARAPALLI	Public	3.77%	3.77%	0.00%
VENKATARAMANA REDDY MALLELA	Public	2.85%	2.85%	0.00%
PRADEEPKUMAR M G	Public	2.65%	2.65%	0.00%
RADHA KRISHNA DORADLA	Public	2.57%	—	—
K S SRINIVAS RAO	Public	1.90%	1.90%	0.00%
KUNAPAREDDY BALA GOPALAKRISHNARAO	Public	1.28%	—	—
NITIN GUPTA	Public	1.14%	1.14%	0.00%

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%
ASTAL LABORATORIES LIMITED S	256	58.47	26.34	3.70%	+122.70% TTM	+4.39% TTM	-39.66%

Filings & corporate actions

Recent announcements

Submission of certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018.14 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Submission of Voting Results.30 Sep 2026 · AGM/EGM / AGM
Submission of voting Results with scrutinizers report.30 Sep 2026 · AGM/EGM / AGM
Submission of Trading window closure Intimation.30 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Attached.30 Sep 2026 · Company Update / General
Attached30 Sep 2026 · Company Update / General
Submission of outcome of 33rd Annual General Meeting.29 Sep 2026 · AGM/EGM / AGM
Submission of Intimation under SEBI (PIT) Regulations, 2015.11 Sep 2026 · Company Update / Code of Conduct under SEBI (PIT) Regulations, 2015
Submission of newspaper publication of AGM Notice.9 Sep 2026 · Company Update / Newspaper Publication
Attached.7 Sep 2026 · Company Update / General
Submission of 33rd AGM Notice.7 Sep 2026 · AGM/EGM / AGM
Submission of Annual Report for the financial year ended March 31, 2026.7 Sep 2026 · Others / Reg. 34 (1) Annual Report
Submission of Intimation of AGM.5 Sep 2026 · AGM/EGM / AGM
Submission of intimation of Appointment of Cost Auditor.5 Sep 2026 · Company Update / General
Submission of outcome of the meeting of the Board of Directors.4 Sep 2026 · Board Meeting / Outcome of Board Meeting
Astal Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/09/2026 ,inter alia, to consider and approve 1. To Consider & to approve ....31 Aug 2026 · Board Meeting / Board Meeting
Submission of Newspaper publication of financial results for the quarter ended 30th June, 2026.16 Aug 2026 · Company Update / Newspaper Publication
Submission of Statement of Deviation & Variation14 Aug 2026 · Company Update / Reg. 32 (1), (3) - Statement of Deviation & Variation
Submission of Financial Results for the quarter ended June 30, 2026.14 Aug 2026 · Result / Financial Results
Submission of Outcome of Board Meeting.14 Aug 2026 · Board Meeting / Outcome of Board Meeting
Astal Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 ,inter alia, to consider and approve Prior intimation of Board ....9 Aug 2026 · Board Meeting / Board Meeting
Submission of Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 201816 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Submission of Trading Window Closure Intimation.29 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
Outcome of board meeting held on today i.e. 29th June, 2026.29 Jun 2026 · Others / Outcome without intimation
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. <table border=''1px''><tr> <td>Sr. No.</td> <td>Particulars</td> <td>Details</td> ....22 Jun 2026 · Others / Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Newspaper publication.15 Jun 2026 · Company Update / Newspaper Publication
Submission of newspaper publication for financial results for the quarter and year ended March, 2026.2 Jun 2026 · Company Update / Newspaper Publication
Intimation of authorization of KMPs under regulation 30 (5) of SEBI (LODR), Regulations, 2015.1 Jun 2026 · Company Update / General
Internal Auditor appointment for the financial year 2026-27.31 May 2026 · Company Update / General
Financial Results for quarter and year ended March 31, 202630 May 2026 · Result / Financial Results
Statement of Deviation and variation30 May 2026 · Company Update / Reg. 32 (1), (3) - Statement of Deviation & Variation
Audited standalone and consolidated financial results for the quarter and financial year ended March. 31, 2026.30 May 2026 · Result / Financial Results
Outcome of Board Meeting held on Saturday, 30th May, 2026.30 May 2026 · Board Meeting / Outcome of Board Meeting
Annual Secretarial Compliance Report for the period March 31, 2026.27 May 2026 · Company Update / Reg.24(A)-Annual Secretarial Compliance
Intimation of Lapse and forfeiture of Convertible Warrants allotted on 27th November, 2024.26 May 2026 · Company Update / General
Intimation of Allotment of equity shares pursuant to conversion of warrants.26 May 2026 · Company Update / Allotment of Equity Shares
Astal Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 ,inter alia, to consider and approve 1. To Consider and Approve ....25 May 2026 · Board Meeting / Board Meeting
Outcome of Board meeting held today, 25th May, 2026.25 May 2026 · Others / Outcome without intimation
Intimation of appointment of statutory auditor in material wholly owned subsidiary company to fill the casual vacancy due to resignation.20 May 2026 · Company Update / Appointment of Statutory Auditor/s
Monitoring Agency report for the quarter ended 31st March, 2026.15 May 2026 · Company Update / Monitoring Agency Report

Board meetings

14 Aug 2026 Board Meeting - Financial Results